
Latus Bio announces $97 million series A financing
Gene therapy company Latus Bio has closed a $97 million Series A financing to support its therapeutics pipeline. The financing includes a $43 million extension led by 8VC, with participation from existing investors DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, and Hatch BioFund. Korea Development Bank… Read More
